BioPharma Services, a subsidiary of HEALWELL AI, is expanding its capabilities into late-stage patient trials through the integration of Canadian Phase Onward (CPO). This strategic move aims to create a full-service Contract Research Organization (CRO) capable of managing clinical trials across all phases of drug development, leveraging HEALWELL's AI platform to enhance research and patient identification.
Strategic Integration Details
The integration of CPO, a clinical research site within HEALWELL's Polyclinic Family and Specialty Medicine Facility, marks a significant milestone for BioPharma. CPO's expertise in patient enrollment and trial execution will be pivotal in facilitating late-stage trials. This expansion supports HEALWELL's broader vision of building robust clinical research capabilities and leveraging synergies across its business lines to drive growth and innovation in healthcare.
"BioPharma is an industry leader in early phase trials, and integrating them with our CPO division immediately leverages our synergies to create a more robust and complete end-to-end platform for life science customers," said Dr. Alexander Dobranowski, CEO of HEALWELL. He further emphasized the unique opportunity to leverage AI capabilities to efficiently identify at-risk patients for clinical research.
AI Integration for Enhanced Efficiency
BioPharma will also integrate HEALWELL AI's data science and artificial intelligence platform to advance research and development, disease detection, and patient identification capabilities. This integration aims to modernize patient search and identification, leading to increased efficiencies and reduced costs in patient trials.
Anna Taylor, Managing Director at BioPharma, expressed excitement about the integration, stating, "This integration not only broadens our reach into patient trials but also strengthens our capacity to deliver comprehensive clinical research services that are vital to our clients and the industry."
Benefits of the Integration
The strategic benefits of this integration include:
- Expanded Capabilities: BioPharma can now offer comprehensive clinical trial services from early-phase to late-stage.
- Increased Patient Access: CPO's existing patient base and research capabilities, combined with HEALWELL's access to patient populations, facilitate faster recruitment and enhanced trial diversity.
- Enhanced Research Infrastructure: Polyclinic provides a robust referral network, ensuring comprehensive care and potential access to novel treatment options for patients.
- Growth of Clinical Research: This integration supports a broader vision to expand clinical research capabilities and build a patient-focused model.
CPO's Role and Expertise
CPO has been managing clinical trials and patient studies for over a decade, specializing in various fields, including psychiatry, pain management, endocrinology, gastroenterology, neurology, cardiology, and respiratory medicine. Its collaboration with the Polyclinic ensures continuity of care for study patients through regular communication with their physicians. CPO will play a vital role in providing access to late-phase clinical trial operations, including patient enrollment directly from the family practice.
BioPharma Services has completed over 2,200 clinical trials since its inception, working with approximately 250 pharmaceutical clients globally, including four of the top 25 largest pharmaceutical companies in the world.
